1971 Investors following Elder Pharma. Share this News with them.
0
Like this story, share it with millions of investors on M3
Elder Pharma joins hands with Spanish co
Elder Pharmaceuticals Ltd has entered into an alliance with Spain's Laboratorios Farmaceuticos Rovi SA to market advanced heparins or anti-thrombotics in India for treatment and prevention of diseases like deep vein thrombosis and pulmonary embolism.
Elder Pharmaceuticals Ltd has entered into an alliance with Spain's Laboratorios Farmaceuticos Rovi SA to market advanced heparins or anti-thrombotics in India for treatment and prevention of diseases like deep vein thrombosis and pulmonary embolism.
Heparins are used as anti-coagulants to prevent blood from clotting.
Joint Initiative
Laboratorios Farmaceuticos Rovi SA is a 100-million research-backed pharmaceutical company that invests 18 per cent of its turnover in research.
The joint initiative between the two companies will see the introduction of Bemiparin in India - the patented, second-generation heparin used in the prevention and treatment of thrombo-embolic venous diseases - a note from the company said.
In India, Bemiparin is likely to be launched in a couple of months under the HIBOR brandname, and the price of the medicine would be firmed-up then, an industry representative familiar with the development said.
The total anti-thrombotic market in India is estimated to be about Rs 130 crore with products largely from multinational companies including Sanofi-Aventis and Novartis , the note added.
The joint initiative between the two companies will see the introduction of Bemiparin in India - the patented, second-generation heparin used in the prevention and treatment of thrombo-embolic venous diseases - a note from the company said. 
